[1] Zhang GJ, Wang JF, Li WR, Zhang YP, Shen ZX. Clinical characteristics of bone metastasis from gastric cancer[J]. Chinese Journal of Clinical Oncology, 2015, 42(09) : 457- 459. http://dx.chinadoi.cn/10.3969/j.issn.1000-8179.20150049.
[2] He J, Zeng ZC, Yang P, Chen B, Jiang W, Du SS. Clinical features and prognostic factors for patients with bone metastases from prostate cancer[J]. Asian Journal of Andrology, 2012, 14(3):505-508. http://dx.chinadoi.cn/10.1038/aja.2012.24.
[3] Kobayashi M, Araki K, Matsuura K, Kawai S, Moriki T. Early gastric cancer giving rise to bone and brain metastases- A review of the Japanese literature. Hepatogastroenterology, 2002, 49: 1751-1754. https://doi.org/10.1136/gut.51.5.757.
[4] Zhang H, Zhang RP, Li FX, Quan JC, Liu H, Deng JY, et.al. Clinicopathological characteristics and prognostic analysis of bone metastasis in gastric cancer patients[J]. Chinese journal of gastrointestinal surgery, 2013, 16(4):354-357. http://dx.chinadoi.cn/10.3760/cma.j.issn.1671-0274.2013.04.014.
[5] Kimura A, Kawasaki H, Wajima N, Nakai M, Nakayama Y, Yonaiyama S, et.al. A case of rapidly fatal gastric cancer with disseminated carcinomatosis of the bone marrow[J] . Gan To Kagaku Ryoho, 2013, 40: 2322-4.
[6] Yoshikawa K, Kitaoka H. Bone metastasis of gastric cancer. Jpn J Surg 1983, 13: 173- 176. https://doi.org/10.1007/BF02469472.
[7] Yamamura Y, Kito T, Yamada E. Clinical evaluation of bone and bone marrow metastasis of gastric carcinoma. Jpn J Gastroenterol Surg 1985, 18: 2288-2293. https://doi.org/10.5833/jjgs.18.2288.
[8] Xu HM. Early diagnosis and treatment evaluation of bone metastasis in patients with gastric carcinoma[J]. China Journal of Practical Surgery, 1996, 16(11) : 644. http://dx.chinadoi.cn/10.3321/j.issn:1005-2208.1996.11.003.
[9] Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et.al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. Journal of evidence-based medicine. 2015, 8(1) : 2-10. https://doi.org/10.1111/jebm.12141.
[10] Chen N, Zhang W, Feng WM, Chen ZX. Analysis of 45 bone metastasis in patients with gastric cancer[J]. Journal of Practical Medicine. 1996, 12(10) : 678- 679.
[11] Feng WM, Chen ZX, Chen N. Diagnosis and treatment of 36 bone metastasis in patients with gastric carcinoma. Chinese Journal of Clinical Cancer, 1997, 24(10) : 772- 773.
[12] Xie CH, Wang JQ. Study on related factors of bone metastasis in patients with gastric cancer[J]. Journal of Henan Medical University, 1997, 04: 1000- 1069. http://dx.chinadoi.cn/10.13705/j.issn.1671-6825.1997.04.019.
[13] Yu HM, Ding S, Sun JC. Analysis and treatment of 250 bone metastasis in patients with advanced cancer[J]. Tumor, 1998, 18(04) : 295- 298.
[14] Dai XY. Clinical analysis of 14 bone metastasis in patients with gastric cancer[J]. Journal of Oncology, 1998, 11(06) : 487.
[15] Yuan YJ. Clinical analysis of 53 bone metastasis in patients with gastric cancer[J]. Journal of Clinical Oncology, 2001, 06(03) : 252- 253. http://dx.chinadoi.cn/10.3969/j.issn.1009-0460.2001.03.021.
[16] Chen YX, Qin SK, Qian J, He ZM, Wang L, Shao ZJ, et al. Clinical analysis of 20 bone metastasis in patients with gastric cancer[J]. Chinese Journal of Oncology Clinical and Rehabilitation, 08(01) : 68- 69. http://dx.chinadoi.cn/10.3969/j.issn.1005-8664.2001.01.031.
[17] Xiao BW. Clinical Assessment of Bone Metastasis in 36 Postoperative Gastric Cancer Patients[J]. Chinese Journal of Clinical Oncology, 2002, 29(7) : 471- 473. http://dx.chinadoi.cn/10.1016/S0731-7085(02)00079-1.
[18] Chen DZ, Tang MD, Jin X. Clinical analysis of bone scintigraphy in 147 patients with gastric cancer[J]. Medical Journal, 2003, 25(04) : 56- 57. http://dx.chinadoi.cn/10.3969/j.issn.1002-2600.2003.04.034.
[19] Ding Y, Tian JH, Yao SL, Zhang SW, Shao MZ, Wei B, et al. Applications Value of 18FDG- PET in Diagnosis of Gastric Cancer[J]. Journal of Isotopes, 2004, 17(01) : 27- 30. http://dx.chinadoi.cn/10.3969/j.issn.1000-7512.2004.01.007.
[20] Zhang B, Chen ZJ, Cheng LL. Analysis of Whole Body Bone Scanning by 63 Patients with Gastric Cancer[J]. The Practical Journal of Cancer, 2006, 21(06) : 626- 627. http://dx.chinadoi.cn/10.3969/j.issn.1001-5930.2006.06.024.
[21] Hou PF, Zhang XF, Zheng ZW. Clinicopathological features of early gastric cancer and long-term outcome of surgical treatment[J]. Chinese Journal of Gastrointestinal surgery, 2007, 10 (2): 121- 121. http://dx.chinadoi.cn/10.3760/cma.j.issn.1671-0274.2007.01.013.
[22] Lee KW, Kim JH, Yun T, Song EK, Na II, Shin H, et.al. Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer[J]. Journal of Korean Medical Science, 2007, 22(6): S115–S121. https://doi.org/10.3346/jkms.2007.22.s.s115.
[23] Hiraiwa K, Takeuchi H, Hasegawa H, Saikawa Y, Suda K, Ando T, et.al. Clinical Significance of Circulating Tumor Cells in Blood from Patients with Gastrointestinal Cancers[J]. Annals of Surgical Oncology, 2008, 15(11):3092-3100. https://doi.org/10.1245/s10434-008-0122-9.
[24] Park Y, Kim JW, Kim DS, Kim EB, Park SJ, Choi WS, et.al. The Bone Morphogenesis Protein-2 (BMP-2) is Associated with Progression to Metastatic Disease in Gastric Cancer[J]. Cancer Research and Treatment, 2008, 40(3). https://doi.org/10.4143/crt.2008.40.3.127.
[25] Zheng SP, Wu LW. Surgical treatment of gastric cancer: clinical analysis of 252 cases. China Health Care, 2010, 19(14) : 35- 36.
[26] Zheng J, Gao S. Clinical value of 18F-FDG PET/CT imaging in the diagnosis and stages of gastric carcinoma. Master Thesis of Medical University of Tianjin.
[27] Lim DH, Park SH, Park KW, Kang JH, Oh SY, Hwang IG, et.al. Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer[J]. BMC Cancer,10,1(2010-10-26), 2010, 10(1):583. https://doi.org/10.1186/1471-2407-10-583.
[28] Li CP, Chen JS, Chen LT, Yen CJ, Lee KD, Su WP, et.al. A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer[J]. BRITISH JOURNAL OF CANCER, 2010, 103(9):1343-1348. https://doi.org/10.1038/sj.bjc.6605928.
[29] Bao JC, Zhou WL, Wang QS, Li CH, Huang YH. The Diagnostic Value of 18F-FDG PET/CT Imaging in Recurrence and Metastasis of Gastric Cancer after Operation. Master Thesis of Southern Medical University. http://dx.chinadoi.cn/10.3969/j.issn.1008-1062.2010.10.005.
[30] Peng SM, Tan XD, Xie YS. Analysis on Characteristics of Whole Body Bone Scanning in 25
Patients with Gastric Cancer and Bone metastases. Chin J Med Imaging Technol, 2011, 27(01) : 204- 205. http://dx.chinadoi.cn/10.13929/j.1003-3289.2011.01.048.
[31] Ahn JB, Ha TK, Kwon SJ. Bone metastasis in gastric cancer patients[J]. J Gastric Cancer, 2011, 11: 38-45. https://doi.org/10.5230/jgc.2011.11.1.38.
[32] Park HS, Rha SY, Kim HS, Hyung WJ, Park JS, Chung HC, et.al. A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis. Oncology, 2011, 80: 142- 150. https://doi.org/10.1159/000328507.
[33] Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, et.al. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer[J]. Bmc Cancer, 2011, 11(1):489. https://doi.org/10.1186/1471-2407-11-489.
[34] Ren Y, Zhang X, Zhuang K. An Analysis on Radioactive Bone Imaging in 297 Patients with Bone Metastasis from Gastrointestinal Cancer. China Cancer, 2013, 22(07) : 596- 598. http://dx.chinadoi.cn/10.11735/j.issn.1004-0242.2013.07.A017.
[35] Jeong JH, Lim SM, Yun JY, Rhee GW, Lim JY, Cho JY, et.al. Comparison of Two Inflammation-Based Prognostic Scores in Patients with Unresectable Advanced Gastric Cancer. Oncology, 2012, 83: 292- 299. https://doi.org/10.1159/000342376.
[36] Hwang JE, Kim HN, Kim DE, Shim HJ, Bae WK, Hwang EC, et.al. First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status[J]. Experimental & Therapeutic Medicine, 2012, 4(4):562-568. https://doi.org/10.3892/etm.2012.644.
[37] Park JM, Song KY, O JH, Kim WC, Choi MG, Park CH. Bone Recurrence after Curative Resection of Gastric Cancer. J Gastric Cancer, 2013, 16(03) : 362- 369. https://doi.org/10.1007/s10120-012-0193-y.
[38] Silvestris N, Pantano F, Ibrahim T, Gamucci T, Vita FD. Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. Gastric Carcinoma Bone Disease, 2013, 08(10) : e74402. https://doi.org/10.1371/journal.pone.0074402.
[39] Ma DW, Kim JH, Jeon TJ, Lee YC, Yun M, Youn YH, et.al. 18F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography for the Evaluation of Bone Metastasis in Patients with Gastric Cancer. Digestive and Liver Disease, 2013, 45: 769- 775. https://doi.org/10.1016/j.dld.2013.02.009.
[40] Le W, Xiong JP. The assess of the quality of life in cancer patients. Master Thesis of Medical University.
[41] Bao WJ, Mao XB, Ding CW, Li N. The Value of Radionuclide Whole Body Bone Imaging in the Diagnosis of Bone Metastasis in Patients with Gastric Cancer. Practical Medicine, 2013, 29(06) : 390- 392.
[42] Kadokura M, Iwasa S, Honma Y, Kato K, Hamaguchi T, Yamada Y, et.al. Weekly paclitaxel as second-line chemotherapy in Japanese patients with advanced gastric cancer[J]. Anticancer Research, 2013, 33(10):4547. https://doi.org/10.1097/COC.0b013e31821dee4e.
[43] Lu BS, Zhao LM. Diagnostic value of Serum CA72-4, CA19-9 combined with whole body Bone Imaging in Bone Metastasis of gastric Cancer[J]. Chinese and Foreign Health Abstracts, 2013 (27): 109-110.
[44] Hwang JE, Hong JY, Kim K, Kim SH, Choi WY, Kim MJ, et.al. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer[J]. Bmc Cancer, 2013, 13(1):431-431. https://doi.org/10.1186/1471-2407-13-431.
[45] Nakamura K, Tomioku M, Nabeshima K, Yasuda S. Clinicopathologic Features and Clinical Outcomes of Gastric Cancer Patients with Bone Metastasis. Tokai J Exp Clin Med. , 2014, 39(04) : 193- 198.
[46] Turkoz FP, Solak M, Kilickap S, Ulas A, Esbah O, Oksuzoglu B, et.al. Bone Metastasis from Gastric Cancer: The Incidence, Clinicopathological Features, and Influence on Survival[J]. J Gastric Cancer, 2014, 14(03) : 164- 172. https://doi.org/10.5230/jgc.2014.14.3.164.
[47] Koo DH, Ryu MH, Ryoo BY, Seo J, Lee MY, Chang HM, et.al. Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution[J]. Gastric Cancer, 2015, 18(2):346-353. https://doi.org/10.1007/s10120-014-0385-8.
[48] Xie XL, Liu BP. Experimental and clinical study of multiple imaging agents PET/CT imaging in the evaluation of gastric cancer[D]. Zhengzhou University, 2014.
[49] Yang P, Gu XP, Zhang ZM. Expression of osteopontin in serum of patients with gastric cancer and its role in tumor metastasis[J]. Chinese Journal of Experimental surgery, 2014, 31 (7): 1570-1572. http://dx.chinadoi.cn/10.3760/cma.j.issn.1001-9030.2014.07.061.
[50] Shen L, Li J, Xu J, Pan H, Dai G, Qin S, et.al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)[J]. Gastric Cancer, 2015, 18(1):168-176. https://doi.org/10.1007/s10120-014-0351-5.
[51] Hwang IG, Choi JH, Park SH, Oh SY, Kwon HC, Lee SI, et.al. Chemotherapy in advanced gastric cancer patients associated with disseminated intravascular coagulation[J]. Cancer Research & Treatment, 2014, 46(1):27-32. https://doi.org/10.4143/crt.2014.46.1.27.
[52] Zhong HQ, Zhang HQ, Lu S, He B, Mai WL, Wan YY. Clinical pathological analysis of 97 bone metastasis in patients with gastric cancer[J]. Chinese Journal of Cancer Prevented and Treated, 2015, 22(05) : 373- 377. http://dx.chinadoi.cn/10.16073/j.cnki.cjcpt.2015.05.011.
[53] Zuo W, Wu HB, Wang QS, Li HS, Zhou WL, Dong Y. The value of milk contrast medium filling method in the diagnosis of gastric cancer by 18F-FDG PET/CT [J]. Nuclear Technology, 2014, 37 (12): 29-34.
[54] Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic Spread in Patients with Gastric Cancer. Oncotarget, 2016, 07(32) : 52307- 52316. https://doi.org/10.18632/oncotarget.10740.
[55] Wang J, Qu JL, Li Z, Che XF, Zhang JD, Liu J, et al. A Prognostic Model in Metastatic or Recurrent Gastric Cancer Patients with Good Performance Status Who Received First-Line Chemotherapy. Translational Oncology, 09(03) : 256- 261. https://doi.org/10.1016/j.tranon.2016.04.004.
[56] Sun FY, Li JF, Han CW. Analysis of Prognostic Factors in Patients with Gastric Cancer after Radical Resection. Chin J Clinicians, 2016, 10: 139- 140.
[57] Shen W, Wu YW. The value of 18F-FDG PET/CT imaging in diagnosis and treatment of gastric cancer [D]. 2016.
[58] Seo S, Park SJ, Ryu MH, Park SR, Ryoo BY, Park YS, et.al. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers[J]. Oncotarget, 2017, 8(20):33844-33854. https://doi.org/10.18632/oncotarget.12953.
[59] Kawanaka Y, Kitajima K, Fukushima K, Mouri M, Doi H, Oshima T, et.al. Added value of pretreatment 18 F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT[J]. European Journal of Radiology, 2016, 85(5):989-995. https://doi.org/10.1016/j.ejrad.2016.03.003.
[60] Ding CM, Li N, Mao XB, Bao WJ, Li HL, Fan J. Diagnostic value of 18F-FDG SPECT/CT for recurrence and metastasis of gastric cancer after operation[J]. Jiangsu Medicine, 2017 (11). http://dx.chinadoi.cn/10.19460/j.cnki.0253-3685.2017.11.023.
[61] Wang X, Ban LY. Clinical characteristics of 133 patients with locally advanced gastric cancer after radical operation[D]. 2017.
[62] Kou FR, Lu M, Gong JF, Shen L. Single Center Analysis of the characteristics and Prognostic factors of 146 patients with Bone Metastasis of gastric Cancer[J]. Chinese Cancer Clinical, 2017, 44 (12): 594-599. http://dx.chinadoi.cn/10.3969/j.issn.1000-8179.2017.12.469.
[63] Hultman B, Gunnarsson U, Nygren P, Sundbom M, Glimelius B, Mahteme H. Prognostic factors in patients with loco-regionally advanced gastric cancer[J]. World Journal of Surgical Oncology, 2017, 15(1):172. https://doi.org/10.1186/s12957-017-1243-z.
[64] Mikami J, Kimura Y, Makari Y, Fujita J, Kishimoto T, Sawada G, et.al. Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis[J]. World Journal of Surgical Oncology, 2017, 15(1):8. https://doi.org/10.1186/s12957-016-1091-2.
[65] Wang QW, Zhang XT, Lu M. Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer[J]. World Journal of Gastrointestinal Oncology, 2018, 10(1):31-39. https://doi.org/10.4251/wjgo.v10.i1.31.
[66] Chen M, Shu YQ. Influence of metastasis site on prognosis in patients with gastric adenocarcinoma. Chinese Clinical Oncology, 2018, 6:23-6. http://dx.chinadoi.cn/10.3969/j.issn.1009-0460.2018.06.013.
[67] Hayashi K, Yahata T, Muramoto R, Yamamoto N, Takeuchi A, Miwa S, et.al. Factors Associated With Discharge Destination in Advanced Cancer Patients With Bone Metastasis in a Japanese Hospital[J]. Annals of Rehabilitation Medicine, 2018, 42(3):477-482. https://doi.org/10.5535/arm.2018.42.3.477.
[68] Qiu MZ, Shi SM, Chen ZH, Yu HE, Sheng H, Jin Y, et.al. Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER-based study[J]. Cancer Medicine, 2018, 7(Suppl 24). https://doi.org/10.1002/cam4.1661.
[69] Narita Y, Kadowaki S, Oze I, Kito Y, Kawakami T, Machida N, et.al. Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients[J]. Journal of Gastrointestinal Oncology, 2018, 9(1):52-63. https://doi.org/10.21037/jgo.2017.11.08.